Fiche société
NYU Langone Health
Traitements, essais et publications liés.
Traitements50programmes
Essais26liés
Publications38liées
SourceDBlocale
Traitements
50| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 18F-MK-6240This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3). | Alzheimer | Phase 2 | Remyélinisation indirecte / réparation | United States | À vérifier |
| Active taVNSThe aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period. | Maladie rénale chronique, SEP | Non applicable | Traitement symptomatique | United States | À vérifier |
| Active tPBM-2.0This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3). | Alzheimer | Phase 2 | Remyélinisation indirecte / réparation | United States | À vérifier |
| Anodal tDCS of left or right AG or FCThe purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms. | Épilepsie | Non applicable | Traitement symptomatique | United States | À vérifier |
| Empagliflozin 10 MGA 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease. | Maladie rénale chronique | Phase 2 | À vérifier | United States | À vérifier |
| HEAL-SLE: Holistic Energy for Alleviating Lupus SymptomsThe purpose of this study is to assess the efficacy, feasibility, and acceptability of Virtual Reiki therapy as a complementary treatment for patients with systemic lupus erythematosus (SLE). The study also aims to investigate the feasibility, acceptability, and adherence of integrating Virtual Reiki therapy within the healthcare system for patients with SLE. Participants receiving standard of care (SOC) treatment for SLE will continue SOC while receiving research-specific Virtual Reiki therapy once per week for 8 weeks. Each study session will be delivered remotely by a Certified Reiki Practitioner Level II or higher. | Lupus | Non applicable | Traitement symptomatique | United States | À vérifier |
| Herpes Zoster Subunit (HZ/su) VaccineThis randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment. In addition, the investigators hypothesize that immunogenicity of the vaccine in SLE patients will be at least 50% of levels observed in healthy subjects from prior large clinical trials. | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| Home Urine TestingStudy participants enrolled in the SAMPLE Biorepository (s14-00487) who have provided permission to be contacted for future research will be enrolled and randomized (1:1) two-arm controlled) to either 1) perform weekly home-based proteinuria testing in addition to standard of care or 2) standard of care only. Participants randomized to the home-based proteinuria testing arm will perform weekly home-based proteinuria testing in addition to having standard of care and respond to study team's weekly text messages with urine test results for one year. | Lupus | Non applicable | À vérifier | United States | À vérifier |
| HydroxychloroquineWomen with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague symptoms. This heart problem is referred to as congenital heart block (the most serious being third degree complete block) and represents damage thought to be caused by these autoantibodies. The heart beats abnormally slowly and almost all children require permanent pacemakers before the age of 20. Importantly, women who have had one child with heart block have a ten-fold higher risk of having another child with the same heart condition. Unfortunately, even close monitoring by special techniques during pregnancy does not reverse complete heart block once it is observed. Thus, treatments aimed at prevention are critical. This study will evaluate for the first time whether hydroxychloroquine, a drug used by many patients with SLE, prevents the development of this heart condition. Data from laboratory experiments suggests that this drug, which crosses the placenta, may decrease the inflammation initiated by the passage of anti-Ro antibodies to the fetus. The study uses a Simon's 2-Stage design, and plans to enroll 19 patients in Stage 1 and 35 patients in Stage 2 if Stage 1 is successful. Patients can already be on hydroxychloroquine or will be started as soon as pregnancy is confirmed. The hope is that fewer than 3 cases of heart block will occur in Stage 1, and fewer than 6 cases will occur out of all 54 patients if Stage 2 is reached. The results of this study are expected to become an integral part of the counseling of women with anti-Ro/La antibodies who are considering pregnancy. | Lupus | Phase 3 | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Lumbar Puncture (LP)Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, \[11C\]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention. | Alzheimer | Non applicable | Traitement symptomatique | United States | À vérifier |
| MemantineDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Alzheimer, Migraine, Sclérose latérale amyotrophique | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| MRI, VenipunctureThis study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients. Avascular necrosis is a disease resulting from the loss of blood supply to the bones which can cause the bone to collapse. The collapse of bone may require a surgical replacement of the joint and can be disabling for life. Avascular necrosis is presently not preventable but research has shown that lipid lowering drugs such as lipitor can reduce or prevent avascular necrosis in animals. We therefore hypothesize that lipitor will reduce the incidence of avascular necrosis in lupus patients taking high dose steroids. | Lupus | Phase 2 | À vérifier | United States | À vérifier |
| Nocturnal polysomnography (NPSG)Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, \[11C\]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention. | Alzheimer | Non applicable | Traitement symptomatique | United States | À vérifier |
| PBI Radiotherapy 6 GyThe purpose of this study is to test whether a radiotherapy regimen of 8 GY x 3 days over 5 days (every other day) is as safe (well-tolerated) and effective as 6 Gy x 5 over five consecutive days | Cancer | Non applicable | À vérifier | United States | À vérifier |
| PBI Radiotherapy 8 GyThe purpose of this study is to test whether a radiotherapy regimen of 8 GY x 3 days over 5 days (every other day) is as safe (well-tolerated) and effective as 6 Gy x 5 over five consecutive days | Cancer | Non applicable | À vérifier | United States | À vérifier |
| PET-MR ScanAfrican-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| PiBAfrican-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| POWERbreathe KH2The primary objective of this study is to evaluate the feasibility and safety of inspiratory muscle training (IMT) when implemented as part of routine inpatient physical therapy care in patients undergoing evaluation for advanced heart therapies. The secondary aim is to determine if IMT improves 6-minute walk test (6MWT), dyspnea, Maximal Inspiratory Pressure (MIP) pre-operatively. Thirdly, to determine if IMT decreases ICU and hospital length of stay post-operatively. | Insuffisance cardiaque | Non applicable | À vérifier | United States | À vérifier |
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| rTMS of left or right angular gyrus (AG) or frontal cortex (FC)The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms. | Épilepsie | Non applicable | Traitement symptomatique | United States | À vérifier |
| SARS-COV-2 mRNA VaccineSevere acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic infection to mild flu-like symptoms to multi system failure and death, resulting in significant morbidity and mortality worldwide. Novel vaccines against the SARS-CoV-2 virus have very recently been developed; however, the effectiveness, immune response, and short- or long-term safety of these vaccines have not been tested in immunocompromised patients on anti-CD-20 therapy for multiple sclerosis (MS) or for other disorders. This study will examine the immune response of the Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus given as standard of care (SOC) in MS patients on ocrelizumab. | SEP | À vérifier | Traitement symptomatique | United States | À vérifier |
| Sham taVNSThe aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period. | Maladie rénale chronique, Parkinson, SEP | Non applicable | Traitement symptomatique | United States | À vérifier |
| Sham TMS3 stimulationThe purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms. | Épilepsie | Non applicable | Traitement symptomatique | United States | À vérifier |
| Sham tPBM-2.0This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3). | Alzheimer | Phase 2 | Remyélinisation indirecte / réparation | United States | À vérifier |
| Transcutaneous electrical nerve stimulation unit (TENS)The purpose of this pilot interventional study is to collect preliminary data on the application of a transcutaneous auricular vagal nerve stimulation (taVNS) device in patients with chronic kidney disease (CKD). This data will enhance understanding of the short-term safety, tolerability and effects of this novel therapeutic approach in the setting of CKD. The primary aims are to investigate the feasibility of the protocol and generate preliminary signals of efficacy and tolerability for two different doses of vagal nerve stimulation. The pilot estimates will be used to design a larger scale study that may lead to potentially targeted interventions to reduce cardiovascular (CV) mortality in the CKD population. | Maladie rénale chronique | Non applicable | À vérifier | United States | À vérifier |
| YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic MechanismsYoung Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers. | Parkinson | À vérifier | À vérifier | United States | À vérifier |
| HydroxychloroquineWomen with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague symptoms. This heart problem is referred to as congenital heart block (the most serious being third degree complete block) and represents damage thought to be caused by these autoantibodies. The heart beats abnormally slowly and almost all children require permanent pacemakers before the age of 20. Importantly, women who have had one child with heart block have a ten-fold higher risk of having another child with the same heart condition. Unfortunately, even close monitoring by special techniques during pregnancy does not reverse complete heart block once it is observed. Thus, treatments aimed at prevention are critical. This study will evaluate for the first time whether hydroxychloroquine, a drug used by many patients with SLE, prevents the development of this heart condition. Data from laboratory experiments suggests that this drug, which crosses the placenta, may decrease the inflammation initiated by the passage of anti-Ro antibodies to the fetus. The study uses a Simon's 2-Stage design, and plans to enroll 19 patients in Stage 1 and 35 patients in Stage 2 if Stage 1 is successful. Patients can already be on hydroxychloroquine or will be started as soon as pregnancy is confirmed. The hope is that fewer than 3 cases of heart block will occur in Stage 1, and fewer than 6 cases will occur out of all 54 patients if Stage 2 is reached. The results of this study are expected to become an integral part of the counseling of women with anti-Ro/La antibodies who are considering pregnancy. | Lupus | Phase 2 | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| PET-MR ScanAfrican-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites. However, in a recent community based study of non-demented elderly, black race was associated with higher amyloid burden after adjusting for vascular risk factors, suggesting the presence of additional physiological differences on AD-risk by race in the early stages of the disease. The purpose of this study is to test whether poor slow wave sleep (SWS) quantity (SWS duration) and quality (slow wave activity, SWA) is one of these physiological factors. To test these hypotheses, the investigators will perform community outreach in churches and community-based organizations in Brooklyn and other NYC boroughs with which we have created substantial ties in recent years. In consultation with community stakeholders, the investigators will recruit 150 cognitively normal AA elderly (age 60-75) and 60 age, sex, BMI, income and education matched non-Hispanic whites from the same geographical areas. Investigators will first perform a medical and cognitive evaluation (Visit 1). Participants will then undergo 2 nights of home sleep monitoring using an unattended device to exclude OSA, followed by 7 days of actigraphy with a sleep log to record sleep duration. Both devices will be returned by mail. Subjects with reported total sleep time (TST) between 5 and 10 hours and absence of moderate to severe OSA will be invited to perform a 2-night nocturnal polysomnography (NPSG) (Nights 1-2) and a PiB-PET MR scan (Visit 2). | Alzheimer | À vérifier | À vérifier | United States | À vérifier |
| MemantineDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | Ralentissement de la progression | United States | À vérifier |
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial direct current stimulation (tDCS) as an active control. The primary outcome will be feasibility and the preliminary efficacy data concerning self-reported symptom reduction to inform the design of an intervention, and estimated power needed to complete a larger sham-controlled RCT. We will also measure heart rate variability (HRV), an easily obtained biomarker of vagus nerve stimulation (VNS), in correspondence to intervention response. | SEP | Non applicable | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic MechanismsYoung Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers. | Parkinson | À vérifier | À vérifier | United States | À vérifier |
| MemantineThe purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD) | Alzheimer | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| HEAL-SLE: Holistic Energy for Alleviating Lupus SymptomsThe purpose of this study is to assess the efficacy, feasibility, and acceptability of Virtual Reiki therapy as a complementary treatment for patients with systemic lupus erythematosus (SLE). The study also aims to investigate the feasibility, acceptability, and adherence of integrating Virtual Reiki therapy within the healthcare system for patients with SLE. Participants receiving standard of care (SOC) treatment for SLE will continue SOC while receiving research-specific Virtual Reiki therapy once per week for 8 weeks. Each study session will be delivered remotely by a Certified Reiki Practitioner Level II or higher. | Lupus | Non applicable | Traitement symptomatique | United States | À vérifier |
| HydroxychloroquineWomen with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague symptoms. This heart problem is referred to as congenital heart block (the most serious being third degree complete block) and represents damage thought to be caused by these autoantibodies. The heart beats abnormally slowly and almost all children require permanent pacemakers before the age of 20. Importantly, women who have had one child with heart block have a ten-fold higher risk of having another child with the same heart condition. Unfortunately, even close monitoring by special techniques during pregnancy does not reverse complete heart block once it is observed. Thus, treatments aimed at prevention are critical. This study will evaluate for the first time whether hydroxychloroquine, a drug used by many patients with SLE, prevents the development of this heart condition. Data from laboratory experiments suggests that this drug, which crosses the placenta, may decrease the inflammation initiated by the passage of anti-Ro antibodies to the fetus. The study uses a Simon's 2-Stage design, and plans to enroll 19 patients in Stage 1 and 35 patients in Stage 2 if Stage 1 is successful. Patients can already be on hydroxychloroquine or will be started as soon as pregnancy is confirmed. The hope is that fewer than 3 cases of heart block will occur in Stage 1, and fewer than 6 cases will occur out of all 54 patients if Stage 2 is reached. The results of this study are expected to become an integral part of the counseling of women with anti-Ro/La antibodies who are considering pregnancy. | Lupus | Phase 3 | Immunomodulation + Traitement symptomatique | United States | À vérifier |
| Active taVNSThe aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period. | SEP | Non applicable | Traitement symptomatique | Brazil | À vérifier |
| MemantineThe purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD) | Alzheimer | Phase 2/3 | Neuroprotection + Ralentissement de la progression | Egypt | À vérifier |
| Active taVNSThe aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period. | SEP | Non applicable | Traitement symptomatique | Belgium | À vérifier |
| Home Urine TestingStudy participants enrolled in the SAMPLE Biorepository (s14-00487) who have provided permission to be contacted for future research will be enrolled and randomized (1:1) two-arm controlled) to either 1) perform weekly home-based proteinuria testing in addition to standard of care or 2) standard of care only. Participants randomized to the home-based proteinuria testing arm will perform weekly home-based proteinuria testing in addition to having standard of care and respond to study team's weekly text messages with urine test results for one year. | Lupus | Non applicable | À vérifier | United States | À vérifier |
| Sham TMS3 stimulationThe purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms. | Épilepsie | Non applicable | Traitement symptomatique | United States | À vérifier |
| POWERbreathe KH2The primary objective of this study is to evaluate the feasibility and safety of inspiratory muscle training (IMT) when implemented as part of routine inpatient physical therapy care in patients undergoing evaluation for advanced heart therapies. The secondary aim is to determine if IMT improves 6-minute walk test (6MWT), dyspnea, Maximal Inspiratory Pressure (MIP) pre-operatively. Thirdly, to determine if IMT decreases ICU and hospital length of stay post-operatively. | Insuffisance cardiaque | Non applicable | À vérifier | United States | À vérifier |
| SARS-COV-2 mRNA VaccineSevere acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic infection to mild flu-like symptoms to multi system failure and death, resulting in significant morbidity and mortality worldwide. Novel vaccines against the SARS-CoV-2 virus have very recently been developed; however, the effectiveness, immune response, and short- or long-term safety of these vaccines have not been tested in immunocompromised patients on anti-CD-20 therapy for multiple sclerosis (MS) or for other disorders. This study will examine the immune response of the Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus given as standard of care (SOC) in MS patients on ocrelizumab. | SEP | À vérifier | Traitement symptomatique | United States | À vérifier |
| Active tPBM-2.0This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer's Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham and complete 24 t-PBM/sham treatments, \~11 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3). | Alzheimer | Phase 2 | Remyélinisation indirecte / réparation | United States | À vérifier |
| Herpes Zoster Subunit (HZ/su) VaccineThis randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment. In addition, the investigators hypothesize that immunogenicity of the vaccine in SLE patients will be at least 50% of levels observed in healthy subjects from prior large clinical trials. | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| Active taVNSThe aim of this clinical trial is to determine if trans-auricular vagus nerve stimulation (taVNS) is effective in improving upper extremity function in stroke survivors. The primary objectives include: Investigating whether taVNS improves motor function in stroke survivors. The secondary objectives include: Assessing any potential side effects associated with the method. Investigating taVNS effects on daily routine functions and spasticity Researchers will conduct a comparative analysis between taVNS and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness. Participants in the trial will: Undergo taVNS combined with physical therapy or a sham procedure with physical therapy daily over a two-week period. | Maladie rénale chronique | Non applicable | Traitement symptomatique | United States | À vérifier |
| Nocturnal polysomnography (NPSG)Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, \[11C\]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention. | Alzheimer | Non applicable | Traitement symptomatique | United States | À vérifier |
| Empagliflozin 10 MGA 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease. | Maladie rénale chronique | Phase 2 | À vérifier | United States | À vérifier |
| Transcutaneous electrical nerve stimulation unit (TENS)The purpose of this pilot interventional study is to collect preliminary data on the application of a transcutaneous auricular vagal nerve stimulation (taVNS) device in patients with chronic kidney disease (CKD). This data will enhance understanding of the short-term safety, tolerability and effects of this novel therapeutic approach in the setting of CKD. The primary aims are to investigate the feasibility of the protocol and generate preliminary signals of efficacy and tolerability for two different doses of vagal nerve stimulation. The pilot estimates will be used to design a larger scale study that may lead to potentially targeted interventions to reduce cardiovascular (CV) mortality in the CKD population. | Maladie rénale chronique | Non applicable | À vérifier | United States | À vérifier |
| PBI Radiotherapy 6 GyThe purpose of this study is to test whether a radiotherapy regimen of 8 GY x 3 days over 5 days (every other day) is as safe (well-tolerated) and effective as 6 Gy x 5 over five consecutive days | Cancer | Non applicable | À vérifier | United States | À vérifier |
Essais cliniques
26| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| PBI Radiotherapy 6 Gy | Cancer | Non applicable | NCT02276885 | Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial | COMPLETED |
| Transcutaneous electrical nerve stimulation unit (TENS) | Maladie rénale chronique | Non applicable | NCT05981183 | Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population | RECRUITING |
| Empagliflozin 10 MG | Maladie rénale chronique | Phase 2 | NCT05786443 | SEED — Safety and Efficacy of Empagliflozin in Hemodialysis | ACTIVE_NOT_RECRUITING |
| Nocturnal polysomnography (NPSG) | Alzheimer | Non applicable | NCT04403165 | LEAD — Locus-coeruleus Function in Normal Elderly and AD Risk | COMPLETED |
| Active taVNS | Maladie rénale chronique | Non applicable | NCT06927024 | Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) | RECRUITING |
| Herpes Zoster Subunit (HZ/su) Vaccine | Lupus | Phase 4 | NCT05559671 | Safety of the Herpes Zoster Subunit Vaccine in Lupus | RECRUITING |
| Active tPBM-2.0 | Alzheimer | Phase 2 | NCT04784416 | Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) | COMPLETED |
| SARS-COV-2 mRNA Vaccine | SEP | À vérifier | NCT04843774 | Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA) | COMPLETED |
| POWERbreathe KH2 | Insuffisance cardiaque | Non applicable | NCT07862738 | Inspiratory Muscle Training in Hospitalized Patients With Heart Failure Awaiting Advanced Therapies | NOT_YET_RECRUITING |
| Histotripsie — HistoSonics Edison System | Cancer | Non applicable | NCT07853690 | Histotripsy in Biliary Tract Cancer | RECRUITING |
| Ocrelizumab | SEP | À vérifier | NCT04855617 | Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis | COMPLETED |
| Sham TMS3 stimulation | Épilepsie | Non applicable | NCT03233399 | Modulating Movement Intention Via Cortical Stimulation | RECRUITING |
| Home Urine Testing | Lupus | Non applicable | NCT07823478 | HEALTH Home Urinalysis Testing | RECRUITING |
| Active taVNS | SEP | Non applicable | NCT07017257 | taVNS-PPCS — Transcutaneous Auricular Vagus Nerve Stimulation for Persistent Post-concussion Symptoms | RECRUITING |
| Memantine | Alzheimer | Phase 2/3 | NCT07504198 | Neuroprotection of Memantine and Rosuvastatin | NOT_YET_RECRUITING |
| Active taVNS | SEP | Non applicable | NCT07132021 | Efficacy of Trans-auricular Vagus Nerve Stimulation on Upper Extremity Motor Recovery in Stroke Survivors | RECRUITING |
| Hydroxychloroquine | Lupus | Phase 3 | NCT05799378 | SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | RECRUITING |
| HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms | Lupus | Non applicable | NCT07203157 | HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms | ACTIVE_NOT_RECRUITING |
| Memantine | Alzheimer | Phase 4 | NCT00933608 | Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease | COMPLETED |
| YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms | Parkinson | À vérifier | NCT07752355 | YOPD — Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms | RECRUITING |
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | SEP | Non applicable | NCT06816004 | VANISH-MS — Noninvasive Vagal Nerve Stimulation | ACTIVE_NOT_RECRUITING |
| Memantine | Sclérose latérale amyotrophique | Phase 2 | NCT02118727 | Therapy in Amyotrophic Lateral Sclerosis (TAME) | COMPLETED |
| PET-MR Scan | Alzheimer | À vérifier | NCT03814603 | Sleep AWARE — The Sleep Amyloid, Slow WAve Race and Ethnicity Study | COMPLETED |
| Atorvastatin | Lupus | Phase 2 | NCT00412841 | Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus | TERMINATED |
| Transcranial Direct Current Stimulation (TDCS) | Épilepsie | NA | NCT02263274 | Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS | COMPLETED |
| Hydroxychloroquine | Lupus | Phase 2 | NCT01379573 | Preventive Approach to Congenital Heart Block With Hydroxychloroquine | COMPLETED |
Publications
38| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Transcutaneous electrical nerve stimulation unit (TENS) | Transcutaneous auricular vagus nerve stimulation improves dysautonomia in patients with hypermobile Ehlers-Danlos syndrome. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | ||
| Transcutaneous electrical nerve stimulation unit (TENS) | Optimizing Percutaneous Tibial Nerve Stimulation Intensity for Overactive Bladder Using a Motion Capture System. | Neuromodulation : journal of the International Neuromodulation Society | ||
| Transcutaneous electrical nerve stimulation unit (TENS) | Effects of continuous vs. intermittent transcutaneous electrical stimulation of the auriculotemporal nerve on nociceptive processing: a pilot randomized controlled double-blind crossover trial in asymptomatic volunteers. | Cranio : the journal of craniomandibular practice | ||
| Memantine | Treatment of animal models of Alzheimer's disease with extracellular vesicles or exosomes and involvement of microRNAs. | Neural regeneration research | ||
| Memantine | The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | ||
| Memantine | Pressure-induced suppression of supramolecular dynamics in hydrogen-bonded adamantane derivative. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy | ||
| Hydroxychloroquine | Divergent neurobehavioral effects of hydroxychloroquine and leflunomide in a rat model of rheumatoid arthritis. | Neuropharmacology | ||
| Hydroxychloroquine | Treatment of discoid lupus erythematosus with crisaborole. | The Journal of dermatological treatment | ||
| Hydroxychloroquine | An explainable machine learning model for predicting in-hospital infection in patients with systemic lupus erythematosus. | Renal failure | ||
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Telehealth tDCS to reduce cannabis use: A pilot RCT in multiple sclerosis as a framework for generalized use. | Drug and alcohol dependence | ||
| Memantine | Docking Analysis of Drugs Used in the Treatment of Alzheimer's Disease, Using Cell Membrane Receptors and Enzymes of the Kynurenine Pathway: A Pilot Study. | International journal of molecular sciences | ||
| MRI, Venipuncture | Secondary polycythemia as a rare cause of ischemic stroke: A case report. | Radiology case reports | ||
| MRI, Venipuncture | Iron overload cardiomyopathy. | Heart failure reviews | ||
| Hydroxychloroquine | Eosinophilic Annular Erythema Completely Reactive to Dapson: A Case Report. | The Journal of dermatology | ||
| Hydroxychloroquine | Hydroxychloroquine Exposure Intensity During Early Pregnancy and Composite Fetal Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus: A Retrospective Cohort Study. | Journal of clinical medicine | ||
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines (2017-2025: An update) - endorsed by the European Society for Brain Stimulation (ESBS) and by the International Federation for Clinical Neurophysiology (IFCN). | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology | ||
| Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS) | Exploring the Effects of Remotely Supervised Transcranial Direct Current Stimulation on Motor Outcomes in Multiple Sclerosis: A Systematic Review. | NeuroRehabilitation | ||
| PiB | Defect-Regulated Cubic Prussian Blue Analog Cathodes With Exceptional Stability for Potassium-Ion Batteries. | Small (Weinheim an der Bergstrasse, Germany) | ||
| PiB | High prevalence of tau pathologies in late-onset psychosis: A PET study. | Molecular psychiatry | ||
| PET-MR Scan | Angiogenesis PET/MRI predicts initial growth of sporadic vestibular schwannomas: a prospective study with follow-up in 29 patients using [Ga]Ga-NODAGA-E[c(RGDyK)]. | EJNMMI research | ||
| PET-MR Scan | Multimodal topographic properties of white matter functional segregation in Alzheimer's disease: A simultaneous PET/MR study. | European journal of radiology | ||
| Hydroxychloroquine | Symbiosis modulates pharmaceutical toxicity and contaminant fate in the Azolla-Nostoc system. | Chemosphere | ||
| Hydroxychloroquine | [Sarcoidosis-associated uveitis: Current status and future prospects]. | La Revue de medecine interne | ||
| Hydroxychloroquine | Cardiopulmonary Manifestations of Systemic Sclerosis: Pathophysiology, Clinical Presentation, and Management. | Cardiology in review | ||
| Hydroxychloroquine | A Rare Diagnostic Dilemma of P-ANCA/MPO Positive Crescentic Glomerulonephritis in an Immunosuppressed Lupus Patient. | Case reports in nephrology | ||
| Hydroxychloroquine | Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers. | Journal of ophthalmology | ||
| MRI, Venipuncture | Interesting neuroimaging findings in a child with hyperlipidemia: a case report. | BMC pediatrics | ||
| MRI, Venipuncture | Nurse led first seizure clinics-a dangerous experiment or an effective alternative to the norm? | Epilepsy & behavior : E&B | ||
| Hydroxychloroquine | Purpura as the initial manifestation of IgG4-related disease with concomitant systemic lupus erythematosus: a case report. | Frontiers in medicine | ||
| Hydroxychloroquine | Management of Uncomplicated Plasmodium vivax Malaria in a Pregnant Patient With G6PD Deficiency. | Cureus | ||
| Hydroxychloroquine | Nasal Manifestations of Immunoglobulin A (IgA) Vasculitis in an Adolescent Patient: A Case Report. | Cureus | ||
| Hydroxychloroquine | Atypical Lower Extremity Discoid Lupus Erythematosus Associated With Newly Diagnosed Systemic Lupus Erythematosus in a Male Patient: A Case Report. | Cureus | ||
| Hydroxychloroquine | Hydroxychloroquine-induced retinopathy in Puerto Ricans with systemic lupus erythematosus: Associated factors and early-onset risk. | Lupus | ||
| Hydroxychloroquine | Zeaxanthin Mitigates Hydroxychloroquine-Induced Retinal Toxicity and Metabolic Reprogramming in ARPE-19 Cells. | Journal of biochemical and molecular toxicology | ||
| Hydroxychloroquine | Diagnosis to dialogue: Reproductive health conversations and guideline adherence in women with lupus. | Lupus | ||
| Hydroxychloroquine | Treatments in oral lichen planus: a review. | Frontiers in oral health | ||
| Hydroxychloroquine | Agomelatine for Sjögren's syndrome: a study on its therapeutic effects and mechanisms. | Inflammopharmacology | ||
| Hydroxychloroquine | Targeting lysosomes with a novel chloroquine derivative induces irreversible lysosomal damage and disrupts autophagosome and lysosome assembly in cancer. | Autophagy |